keyword
MENU ▼
Read by QxMD icon Read
search

4CmenB

keyword
https://www.readbyqxmd.com/read/29584565/neisseria-meningitidis-serogroup-b-carriage-by-adolescents-and-young-adults-living-in-milan-italy-prevalence-of-strains-potentially-covered-by-thepresently-available-meningococcal-b-vaccines
#1
Leonardo Terranova, Nicola Principi, Sonia Bianchini, Giada Di Pietro, Giulia Umbrello, Barbara Madini, Susanna Esposito
Recently, two vaccines against meningococcal serogroup B (MenB) have been developed. They are prepared according to the reverse vaccinology approach and contain 4 (4CMenB) and 2 (MenB-FHbp) cross-reactive surface proteins. In Italy 4CMenB vaccine has been included in the official vaccination schedule only recently and recommended only for infants and toddlers, whereas MenB-FHbp is not licensed. In order to collect information about the present carriage of Neisseria meningitidis serogroup B (MenB) in Italian adolescents and to evaluate the potential protection offered by the presently available MenB vaccines, 2,560 otherwise healthy, high school students aged 14-21 years (907 males, 35...
March 27, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29553330/genomic-surveillance-of-4cmenb-vaccine-antigenic-variants-among-disease-causing-neisseria-meningitidis-isolates-united-kingdom-2010-2016
#2
Charlene M C Rodrigues, Jay Lucidarme, Ray Borrow, Andrew Smith, J Claire Cameron, E Richard Moxon, Martin C J Maiden
In September 2015, 4CMenB meningococcal vaccine was introduced into the United Kingdom infant immunization program without phase 3 trial information. Understanding the effect of this program requires enhanced surveillance of invasive meningococcal disease (IMD) Neisseria meningitidis isolates and comparison with prevaccination isolates. Bexsero Antigen Sequence Types (BASTs) were used to analyze whole-genome sequences of 3,073 prevaccine IMD N. meningitidis isolates obtained during 2010-2016. Isolates exhibited 803 BASTs among 31 clonal complexes...
April 2018: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/29523451/prevalence-and-genetic-characteristics-of-4cmenb-and-rlp2086-vaccine-candidates-among-neisseria-meningitidis-serogroup-b-strains-china
#3
Bingqing Zhu, Fenglin Shi, Aiyu Zhang, Xiaofang Sun, Zheng Xu, Li Xu, Yuan Gao, Jing Lv, Zhujun Shao
OBJECTIVE: To systematically investigate the prevalence and genetic characteristics of 4CMenB and rLP2086 vaccine candidates among Neisseria meningitidis serogroup B (NmB) in China. METHODS: A total of 485 NmB strains isolated in 29 provinces of China between 1968 and 2016 were selected from the culture collection of the national reference laboratory according to the isolation year, location, and source. Multi-locus sequence typing (MLST) and porA gene sequencing were performed on all 485 study strains; PCR was used to detect the fHbp, nadA, and nhba gene of 432 strains; positive amplification products from the fHbp and nadA genes from all strains, as well as those of the nhba gene from 172 representative strains, were sequenced...
March 7, 2018: Vaccine
https://www.readbyqxmd.com/read/29487324/human-protective-response-induced-by-meningococcus-b-vaccine-is-mediated-by-the-synergy-of-multiple-bactericidal-epitopes
#4
M Giuliani, E Bartolini, B Galli, L Santini, P Lo Surdo, F Buricchi, M Bruttini, B Benucci, N Pacchiani, L Alleri, D Donnarumma, W Pansegrau, I Peschiera, I Ferlenghi, R Cozzi, N Norais, M M Giuliani, D Maione, M Pizza, R Rappuoli, O Finco, V Masignani
4CMenB is the first broad coverage vaccine for the prevention of invasive meningococcal disease caused by serogroup B strains. To gain a comprehensive picture of the antibody response induced upon 4CMenB vaccination and to obtain relevant translational information directly from human studies, we have isolated a panel of human monoclonal antibodies from adult vaccinees. Based on the Ig-gene sequence of the variable region, 37 antigen-specific monoclonal antibodies were identified and produced as recombinant Fab fragments, and a subset also produced as full length recombinant IgG1 and functionally characterized...
February 27, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29410413/crystal-structure-reveals-vaccine-elicited-bactericidal-human-antibody-targeting-a-conserved-epitope-on-meningococcal-fhbp
#5
Jacinto López-Sagaseta, Peter T Beernink, Federica Bianchi, Laura Santini, Elisabetta Frigimelica, Alexander H Lucas, Mariagrazia Pizza, Matthew J Bottomley
Data obtained recently in the United Kingdom following a nationwide infant immunization program against serogroup B Neisseria meningitidis (MenB) reported >80% 4CMenB vaccine-mediated protection. Factor H-binding protein (fHbp) is a meningococcal virulence factor and a component of two new MenB vaccines. Here, we investigated the structural bases underlying the fHbp-dependent protective antibody response in humans, which might inform future antigen design efforts. We present the co-crystal structure of a human antibody Fab targeting fHbp...
February 6, 2018: Nature Communications
https://www.readbyqxmd.com/read/29374626/4cmenb-and-post-immunisation-fever-an-emerging-hot-topic
#6
Maya Lamoudi, Faye Baxter, Amarpal Bilkhu, Claire Hathorn
No abstract text is available yet for this article.
January 27, 2018: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/29371070/immunogenicity-and-safety-of-the-multicomponent-meningococcal-b-vaccine-4cmenb-in-children-and-adolescents-a-systematic-review-and-meta-analysis
#7
Maria Elena Flacco, Lamberto Manzoli, Annalisa Rosso, Carolina Marzuillo, Mauro Bergamini, Armando Stefanati, Rosario Cultrera, Paolo Villari, Walter Ricciardi, John P A Ioannidis, Despina G Contopoulos-Ioannidis
BACKGROUND: The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However, uncertainties remain about the lowest number of doses required to induce satisfactory, persistent immune responses. We did a systematic review and meta-analysis to provide quantitative estimates for the immunogenicity, persistence of immunogenicity, and safety of 4CMenB vaccine in children and adolescents. METHODS: For this systematic review and meta-analyses (proportion, head to head, and network), we searched MEDLINE, Scopus, Embase, and ClinicalTrials...
April 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29371069/growing-evidence-supports-4cmenb-effectiveness
#8
Shamez N Ladhani, Ray Borrow, Nick J Andrews
No abstract text is available yet for this article.
January 19, 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29337653/safety-and-immunogenicity-of-a-meningococcal-b-recombinant-vaccine-when-administered-with-routine-vaccines-to-healthy-infants-in-taiwan-a-phase-3-open-label-randomized-study
#9
Nan-Chang Chiu, Li-Min Huang, Arnold Willemsen, Chiranjiwi Bhusal, Ashwani Kumar Arora, Zenaida Reynoso Mojares, Daniela Toneatto
Neisseria meningitidis is associated with high mortality and morbidity in infants and children worldwide. This phase 3 study (NCT02173704) evaluated safety and immunogenicity of a 4-component serogroup B recombinant meningococcal vaccine (4CMenB) co-administered with routine vaccines in Taiwanese infants. In total, 225 healthy infants were randomized (2 : 1 ) to receive 4CMenB and routine vaccines (4CMenB+Routine) or routine vaccines only (Routine group) at 2, 4, 6 and 12 months of age. Routine vaccines were diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b, 13-valent pneumococcal, hepatitis B, measles-mumps-rubella and varicella vaccines...
January 16, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/29329168/immune-responses-to-booster-vaccination-with-meningococcal-abcwy-vaccine-after-primary-vaccination-with-either-investigational-or-licensed-vaccines-a-phase-2-randomized-study
#10
Leszek Szenborn, Stan L Block, Teresa Jackowska, Ryszard Konior, Diego D'Agostino, Igor Smolenov, Daniela Toneatto, Jo Anne Welsch
BACKGROUND: Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important Neisseria meningitidis serogroups. METHODS: In this phase 2, randomized, observer-blind, extension study (NCT01272180), participants 10-25 years of age received 1 booster dose of MenABCWY vaccine at 24 months (M) postprimary series of MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose)...
May 2018: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/29246475/estimating-primary-care-attendance-rates-for-fever-in-infants-after-meningococcal-b-vaccination-in-england-using-national-syndromic-surveillance-data
#11
Sally Harcourt, Roger A Morbey, Chris Bates, Helen Carter, Shamez N Ladhani, Simon de Lusignan, Gillian E Smith, Alex J Elliot
BACKGROUND: In September 2015, the United Kingdom became the first country to introduce the multicomponent group B meningococcal vaccine (4CMenB) into a national infant immunisation programme. In early clinical trials 51-61% of infants developed a fever when 4CMenB was administered with other routine vaccines. Whilst administration of prophylactic paracetamol is advised, up to 3% of parents may seek medical advice for fever following vaccination. We used research-level general practitioner consultations to identify any increase in attendances for all-cause fever in vaccine-eligible infants following 4CMenB introduction in England...
January 25, 2018: Vaccine
https://www.readbyqxmd.com/read/29038320/persistence-of-immunity-after-vaccination-with-a-capsular-group-b-meningococcal-vaccine-in-3-different-toddler-schedules
#12
RANDOMIZED CONTROLLED TRIAL
Manish Sadarangani, Tim Sell, Mildred A Iro, Matthew D Snape, Merryn Voysey, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Andrew J Pollard
BACKGROUND: One schedule for the capsular group B meningococcal vaccine 4CMenB is 2 doses that are administered 2 months apart for children aged 12-23 months, with a booster dose 12-24 months later. Our objective was to provide data on persistence of human serum bactericidal antibody (hSBA) titres in children up to 4 years of age after initial doses at 12-24 months, and immunogenicity of a booster dose at 48 months of age compared with vaccine-naive children. METHODS: Children previously immunized, as part of a randomized controlled trial, with 2 doses of 4CMenB vaccine at 12-24 months of age received a booster at 4 years of age...
October 16, 2017: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
https://www.readbyqxmd.com/read/28987549/potential-impact-of-the-4cmenb-vaccine-on-oropharyngeal-carriage-of-neisseria-meningitidis
#13
Raquel Abad, Verónica Medina, Maria Del Carmen Fariñas, Luis Martínez-Martínez, Stefania Bambini, A Dari, Duccio Medini, Mariagrazia Pizza, Julio A Vázquez
The analysis of the potential impact of the meningococcal vaccines in asymptomatic carriers has become one of the key aspects in the evaluation of new vaccines and of their impact on disease control. An important step in this direction is provided by the analysis of the sequence variability and surface-exposure of the 4CMenB (Bexsero®) vaccine antigens, as well as the cross-reactivity of vaccine induced antibodies, in isolates from healthy carriers. The Spanish Reference Laboratory, in collaboration with the University Hospital Marqués de Valdecilla in Santander (Spain), carried out a meningococcal carrier survey between May 2010 and April 2012 (population aged 4 to 19 years)...
October 5, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28931535/risk-of-hospitalisation-with-fever-following-menb-vaccination-self-controlled-case-series-analysis
#14
Heather Murdoch, Lynn Wallace, Jennifer Bishop, Chris Robertson, J Claire Cameron
OBJECTIVE: To investigate a possible association between fever admissions and 4 component Meningococcal B (4CMenB). DESIGN: 4CMenB is given at 8 and 16 weeks in the first year of life. Self-controlled case series using linked routinely collected healthcare data, where the risk period was the 3 days immediately following receipt of a vaccine dose. PATIENTS: Children aged under 1 year in Scotland preintroduction and postintroduction of 4CMenB vaccine (pre-September 2014 to August 2015 and post-September 2015 to June 2016)...
October 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28794096/an-increase-in-accident-and-emergency-presentations-for-adverse-events-following-immunisation-after-introduction-of-the-group-b-meningococcal-vaccine-an-observational-study
#15
Viveka Nainani, Ushma Galal, Jim Buttery, Matthew D Snape
OBJECTIVES: To determine whether the introduction of the capsular group B meningococcal vaccine (4CMenB) in the UK has increased presentations of infants to emergency departments with adverse events following immunisation (AEFI). PARTICIPANTS, DESIGN AND SETTING: A retrospective review of hospital records of infants aged 1-6 months presenting to Oxford University Hospitals NHS Trust's emergency departments from September 2013 to August 2016 with discharge diagnoses of vaccine reactions or non-specific conditions...
August 9, 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28637642/emergency-department-attendance-following-4-component-meningococcal-b-vaccination-in-infants
#16
Sarah Kapur, Thomas Bourke, Julie-Ann Maney, Paul Moriarty
INTRODUCTION: In September 2015, the UK became the first country in the world to introduce the 4-component meningococcal B vaccine(4CMenB) into the routine vaccine schedule for infants. 4CMenB is known to cause fever in infants. Infants presenting with fever, particularly those under 3 months, have a significant risk of serious bacterial infection(SBI). METHOD: Between September 2015 and January 2016, we performed a prospective audit of management of infants between 30 and 180 days attending the regional paediatric emergency department(ED) in Northern Ireland, within 4 days of receiving 4CMenB...
October 2017: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/28624305/durability-of-immunogenicity-and-strain-coverage-of-menbvac-a-meningococcal-vaccine-based-on-outer-membrane-vesicles-lessons-of-the-normandy-campaign
#17
Julien Sevestre, Eva Hong, Valérie Delbos, Aude Terrade, Eric Mallet, Ala-Eddine Deghmane, Ludovic Lemée, Muhamed-Kheir Taha, François Caron
OBJECTIVES: MenBvac® is an outer membrane vesicle (OMV)-based meningococcal vaccine. From 2006 to 2012, it was used to control a clonal B outbreak in Normandy (France). We aimed to analyse the durability of the response against the epidemic strain and coverage beyond the vaccine strain. These data should help to optimize the use of OMV-containing vaccines, such as the new 4CMenB/Bexsero® recombinant vaccine. METHODS: Serum bactericidal activity (SBA) was measured in two cohorts of children who received their first dose of MenBvac® at 1-5years of age and accepted to provide a blood sample either one or four years after a 2+1+1 schedule...
July 13, 2017: Vaccine
https://www.readbyqxmd.com/read/28533054/reduced-schedules-of-4cmenb-vaccine-in-infants-and-catch-up-series-in-children-immunogenicity-and-safety-results-from-a-randomised-open-label-phase-3b-trial
#18
Federico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, Pilar Infante Marquez, Juan Carlos Tejedor Torres, Lily Yin Weckx, Edson Duarte Moreira, Ilhem Mensi, Marco Calabresi, Daniela Toneatto
BACKGROUND: This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. METHODS: In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2+1 doses at 3½-5-11months or 6-8-11months of age, 3+1 doses at ages 2½-3½-5-11months. Children aged 2-10years received 2 catch-up doses administered 2months apart...
June 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28524748/an-unwanted-guest-neisseria-meningitidis-carriage-risk-for-invasive-disease-and-the-impact-of-vaccination-with-insight-on-italy-incidence
#19
Elena Gianchecchi, Giulia Piccini, Alessandro Torelli, Rino Rappuoli, Emanuele Montomoli
Invasive Meningococcal Disease (IMD) represents a potentially life-threatening condition caused by Neisseria meningitidis. The disease is characterized by a case fatality rate of 5-10% whereas serious clinical sequelae can develop in survivors within 12-24 h from the first symptoms. However, IMD infection only occurs rarely, in fact, most of the interactions established between N. meningitidis and the host are harmless, and an estimated 10% of the population asymptomatically carries the bacterium in the nasopharynx...
May 29, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28483197/corrigendum-to-persistence-of-bactericidal-antibodies-following-booster-vaccination-with-4cmenb-at-12-18-or-24months-and-immunogenicity-of-a-fifth-dose-administered-at-4years-of-age-a-phase-3-extension-to-a-randomised-controlled-trial-vaccine-35-2017-395-402
#20
Mildred A Iro, Matthew D Snape, Merryn Voysey, Sena Jawad, Adam Finn, Paul T Heath, Gianni Bona, Susanna Esposito, Javier Diez-Domingo, Roman Prymula, Adefowope Odueyungbo, Daniela Toneatto, Peter Dull, Andrew J Pollard
No abstract text is available yet for this article.
May 31, 2017: Vaccine
keyword
keyword
61758
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"